The DNA polymerase Polκ plays a key role in translesion synthesis, an error-prone replication mechanism. Polκ is overexpressed in various tumor types. Here, we found that melanoma and lung and breast cancer cells experiencing stress from oncogene inhibition up-regulated the expression of Polκ and shifted its localization from the cytoplasm to the nucleus. This effect was phenocopied by inhibition of the kinase mTOR, by induction of ER stress, or by glucose deprivation. In unstressed cells, Polκ is continually transported out of the nucleus by exportin-1. Inhibiting exportin-1 or overexpressing Polκ increased the abundance of nuclear-localized Polκ, particularly in response to the BRAFV600E-targeted inhibitor vemurafenib, which decreased the cytotoxicity of the drug in BRAFV600E melanoma cells. These observations were analogous to how Escherichia coli encountering cell stress and nutrient deprivation can up-regulate and activate DinB/pol IV, the bacterial ortholog of Polκ, to induce mutagenesis that enables stress tolerance or escape. However, we found that the increased expression of Polκ was not excessively mutagenic, indicating that noncatalytic or other functions of Polκ could mediate its role in stress responses in mammalian cells. Repressing the expression or nuclear localization of Polκ might prevent drug resistance in some cancer cells.
Macrophage targeting therapies have had limited clinical success in glioblastoma (GBM). Further understanding the GBM immune microenvironment is critical for refining immunotherapeutic approaches. Here, we use genetically engineered mouse models and orthotopic transplantation-based GBM models with identical driver mutations and unique cells of origin to examine the role of tumor cell lineage in shaping the immune microenvironment and response to tumor-associated macrophage (TAM) depletion therapy. We show that oligodendrocyte progenitor cell lineage-associated GBMs (Type 2) recruit more immune infiltrates and specifically monocyte-derived macrophages than subventricular zone neural stem cell-associated GBMs (Type 1). We then devise a TAM depletion system that offers a uniquely robust and sustained TAM depletion. We find that extensive TAM depletion in these cell lineage–based GBM models affords no survival benefit. Despite the lack of survival benefit of TAM depletion, we show that Type 1 and Type 2 GBMs have unique molecular responses to TAM depletion. In sum, we demonstrate that GBM cell lineage influences TAM ontogeny and abundance and molecular response to TAM depletion.
Excessive Wnt signaling is associated with 1) poor prognosis in triple-negative breast cancer (TNBC) and other cancers and 2) immune checkpoint inhibitor resistance, thus limiting its therapeutic application. From our previous work and Wnt signaling principles, we devised CHA1 as an inhibitor of Wnt signaling. CHA1 combines the green tea catechin EGCG (Epigallocatechin-3-gallate) and the DNA methyltransferase inhibitor decitabine, which have been used in numerous clinical trials and/or FDA approved for other cancers, respectively. Our investigations showed that CHA1 treatment (but not EGCG or decitabine alone) reduced primary tumors and metastases in TNBC xenograft and decreased Wnt signaling. Unexpectedly, CHA1 reprogrammed intrinsic tumor properties for antigen presentation and immune cell infiltration. The implications governing tumor-immune cell interactions are discussed in the context of increasing checkpoint inhibitor susceptibility. Both Immune-compromised and immune-competent TNBC preclinical models were used for mechanistic elaboration. In CHA1-treated human TNBC tumors in immune-compromised mice, biochemical and RNA seq analyses show that Wnt signaling was decreased due to induction of Wnt pathway inhibitors (e.g., SFRP1, DKK1, HBP1). The RNA seq analysis also revealed induction of >100 genes for antigen presentation and associated processes. MHC staining of CHA1-treated tumors verified the genotypic changes, which were also accompanied by robust gamma interferon signaling. All results were recapitulated in the immune-competent 4T1 syngeneic TNBC model. We observed large increases in tumor-infiltrating CD8+ T cells with CHA1 treatment. Lastly, recent reports collated the molecularly disparate properties of a “cold-to-hot” transition, in which “hot” tumors have increased immune cell infiltration and sensitivity to checkpoint inhibitors. Remarkably, the TNBC tumors (typically “cold”) that were treated with CHA1 now exhibited the unrelated list of “hot” tumor properties: 1) epigenetic reprogramming, 2) suppressed Wnt signaling, 3) E-cadherin and epithelial marker re-expression, 4) CD8+ T-cell enrichment, 5) increased tumor antigen presentation properties, and 6) increased tumor PD-L1 expression. The CHA1 mechanism is consistent with a global reprogramming of intrinsic tumor properties, triggered by differential Wnt and interferon signaling. CHA1 engages the fundamental processes that regulate tumor-immune cell dynamics, which, in turn, govern immune cell infiltration and determine checkpoint inhibitor sensitivity. Our work additionally establishes a molecular framework for assessing compounds that engage a fundamental “cold-to-hot” tumor reprogramming and that may predict new immune checkpoint inhibitor sensitivity. Thus, CHA1 treatment may reprogram tumor-immune cell dynamics to significantly expand the spectrum of TNBC and other tumors that can be efficaciously treated with immune checkpoint inhibitors (e.g., anti-PDL1 and/or anti-PD1). Citation Format: Mariam Alamoudi, Mollie Chipman, Francesca Deleso-Frechette, Eileen Liu, Rui Zhang, Zixu Wang, K. Eric Paulsopn, Amy S. Yee. A therapeutic strategy to inhibit Wnt signaling also reprograms breast tumor-immune cell interactions: Perspectives for conferring immune checkpoint inhibitor susceptibility [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2019 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(3 Suppl):Abstract nr A39.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.